Evidence map›Paper›PMID 34312374›Full record

ArticleCell death discovery2021

SENP1 promotes MCL pathogenesis through regulating JAK-STAT5 pathway and SOCS2 expression.

Yali Zhang, Yanni Ma, Guixian Wu, Mingling Xie, Chengxin Luo, Xiangtao Huang, Feng Tian, Jieping Chen, Xi Li

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Cell death discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yali ZhangDepartment of Hematology, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
Yanni MaDepartment of Hematology, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
Guixian WuDepartment of Hematology, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
Mingling XieDepartment of Hematology, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
Chengxin LuoDepartment of Hematology, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
Xiangtao HuangDepartment of Hematology, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
Feng TianDepartment of Hepatobiliary Surgery, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
Jieping ChenDepartment of Hematology, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China. chenjpxn@163.com.
Xi LiDepartment of Hematology, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China. lixi1988xn@163.com.
Southwest Hospital · CN

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81700185National Natural Science Foundation of China (National Science Foundation of China) 81800172
6 · The paper itself

Abstract

Mantle cell lymphoma (MCL) is highly aggressive and its treatment remains challenging, understanding its pathogenesis is critical for future targeted therapy. SUMO specific proteases 1 (SENP1) is an important protein that regulates the balance between SUMOylation and deSUMOylation. We found that SENP1 was upregulated in MCL patient samples and cell lines. Knockdown of SENP1 could inhibit the proliferation and promote the apoptosis of MCL cells. We also found that SENP1 knockdown caused inhibition of the JAK-STAT5 pathway and upregulation of tumor suppressor cytokine signaling 2 (SOCS2). Moreover, MCL tumor growth in vivo was significantly suppressed after SENP1 knockdown in a xenograft nude mouse model. In summary, our results showed that SENP1 is involved in the pathogenesis of MCL and may be a potential therapeutic target.

Identifiers

PMID34312374
PMCPMC8313533
OpenAlexW3186684428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.